Paul Yanning Jiang

Mr. Paul Yanning Jiang

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2020 in Catalysts
Verified
Journal Article
Open access
PDF file
Michelle LangtonMichelle Langton
Michelle Langton
Sining SunSining Sun
Sining Sun
CUChie Ueda
Chie Ueda
MMMax Markey
Max Markey
Jiahua ChenJiahua Chen
Jiahua Chen
Maria-Eirini PandeliaMaria-Eirini Pandelia
Maria-Eirini Pandelia
The histidine–aspartate (HD)-domain protein superfamily contains metalloproteins that share common structural features but catalyze vastly different reactions ranging from oxygenation to hydrolysis. This chemical diversion is afforded by (i) their ability to coordinate most biologically relevant transition metals in mono-, di-, and trinuclear configurations, (ii) sequence insertions or the addition of supernumerary ligands to their active sites, (iii) auxiliary substrate specificity residues vicinal to the catalytic site, (iv) additional protein domains that allosterically regulate their activities or have catalytic and sensory roles, and (v) their ability to work with protein partners. More than 500 structures of HD-domain proteins are available to date that lay out unique structural features which may be indicative of function. In this respect, we describe the three known classes of HD-domain proteins (hydrolases, oxygenases, and lyases) and identify their apparent traits with the aim to portray differences in the molecular details responsible for their functional divergence and reconcile existing notions that will help assign functions to yet-to-be characterized proteins. The present review collects data that exemplify how nature tinkers with the HD-domain scaffold to afford different chemistries and provides insight into the factors that can selectively modulate catalysis.

1 February 2023 in JAMA Dermatology
Verified
Journal Article
Closed access
PDF file
HRHaya S. Raef
Haya S. Raef
LRLina Rebeiz
Lina Rebeiz
RLRebecca Karp Leaf
Rebecca Karp Leaf
OHOlivia Hughes
Olivia Hughes
PJPaul Yanning Jiang
Paul Yanning Jiang
ADAmy Dickey
Amy Dickey
Importance: Erythropoietic protoporphyria (EPP) is a rare and underdiagnosed genetic disease characterized by painful sensitivity to light. A better understanding and characterization of its light-induced cutaneous symptoms may aid in the identification of EPP in patients.Objectives: To describe the cutaneous symptoms of erythropoietic protoporphyria (EPP) and to determine if these symptoms are associated with the degree of light sensitivity.Design, Setting, and Participants: This was a cross-sectional study of adolescent and adult (≥15 years) patients with EPP across the US conducted by a single academic hospital via a remotely administered survey, measurements of light sensitivity by light dosimetry and by text message symptom assessments. Data analyses were conducted from November 2020 to April 2022.Exposures: Sunlight exposure.Main Outcomes and Measures: Self-reported symptoms and association with measured light sensitivity.Results: The study sample consisted of 35 patients with EPP (mean [SD] age, 39.1 (15.5) years; 21 [60%] female; 14 [40%] male; 35 [100%] White individuals). The patients’ median [range] skin tone was 3.0 (1.0-8.0), based on self-reporting from 1 (lightest) to 12 (darkest). A total of 24 participants completed the light dosimeter measurements. Phototoxic reactions were characterized by pain (97%; 34 patients), burning (97%; 34), tingling (97%; 34), pruritus (83%; 29), allodynia (89%; 31), improvement of symptoms with cold (89%; 31), achiness (24%; 12), fatigue (46%; 16), mild swelling (83%; 29), severe swelling (63%; 22), erythema (51%; 18), petechiae (40%; 14), skin cracking (43%; 15), scabbing (46%; 16), scarring (66%; 23), and other chronic skin changes (40%; 14). Patients with EPP reported that their hands, feet, and face were most sensitive to light and that their shoulders and legs were least sensitive; 25.7% (9 patient) reported no chronic skin changes, and 5.7% (2 patients) reported never having had any visible symptoms. None of these findings varied with the degree of light sensitivity except that lower overall light sensitivity was associated with lower ranked sensitivity of the neck and arms.Conclusions and Relevance: The findings of this cross-sectional study suggest that patients with EPP have distinctive cutaneous symptoms that may aid in identification of this underdiagnosed disease. Characteristic EPP symptoms include light-induced cutaneous burning pain and occasional swelling, particularly over the hands, with a prodrome of pruritus and paresthesias. Minimal skin changes or the absence of visible skin changes during reactions to light, including lack of erythema, do not exclude an EPP diagnosis nor suggest low EPP disease burden.

21 February 2022 in Biochemistry
Verified
Journal Article
Closed access
SSSining Sun
Sining Sun
ZHZunyu He
Zunyu He
PJPaul Yanning Jiang
Paul Yanning Jiang
RBRishika Baral
Rishika Baral
Maria-Eirini PandeliaMaria-Eirini Pandelia
Maria-Eirini Pandelia

28 May 2024 in Life
Verified
Journal Article
Open access
PDF file
RLRebecca K. Leaf
Rebecca K. Leaf
HNHetanshi Naik
Hetanshi Naik
PJPaul Yanning Jiang
Paul Yanning Jiang
SESarina Elmariah
Sarina Elmariah
PHPamela Hodges
Pamela Hodges
ADAmy Dickey
Amy Dickey
Background: Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are rare disorders of heme biosynthesis characterized by severe cutaneous phototoxicity. Afamelanotide, an α-melanocyte-stimulating hormone analogue, is the only approved treatment for protoporphyria and leads to increased light tolerance and improved quality of life (QoL). However, published experience with afamelanotide in the US is limited. Methods: Here, we report on all adults who received at least one dose of afamelanotide at the Massachusetts General Hospital Porphyria Center from 2021 to 2022. Changes in the time to phototoxic symptom onset, QoL, and laboratory parameters were assessed before and during treatment with afamelanotide. Results: A total of 29 patients with protoporphyria were included, 26 of whom (72.2%) received ≥2 afamelanotide implants. Among the patients who received ≥2 implants, the median time to symptom onset following sunlight exposure was 12.5 min (IQR, 5–20) prior to the initiation of afamelanotide and 120 min (IQR, 60–240) after treatment (p < 0.001). Improvements in QoL during afamelanotide treatment were measured using two QoL tools, with good correlation observed between these two instruments. Finally, we found no improvements in the median levels of metal-free erythrocyte protoporphyrin, plasma protoporphyrin, or liver biochemistries during versus prior to the initiation of afamelanotide treatment. Conclusions: This study highlights a dramatic clinical benefit of afamelanotide in relation to light tolerance and QoL in protoporphyria, albeit without improvement in protoporphyrin levels or measures of liver function.

10 June 2025 in British Journal of Haematology
Verified
Journal Article
Closed access
RLRebecca K. Leaf
Rebecca K. Leaf
ARAndrea Ricci
Andrea Ricci
BTBenny Tran
Benny Tran
ECElena Corradini
Elena Corradini
APAntonello Pietrangelo
Antonello Pietrangelo
ADAmy Dickey
Amy Dickey

11 April 2024 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
ADAmy Dickey
Amy Dickey
JBJaime Berkovich
Jaime Berkovich
RLRebecca K. Leaf
Rebecca K. Leaf
PJPaul Yanning Jiang
Paul Yanning Jiang
GLGisela Lopez‐Galmiche
Gisela Lopez‐Galmiche
JCJan‐Kai Chang
Jan‐Kai Chang